Briumvi significantly outperformed Aubagio at reducing disease activity in people with highly active relapsing forms of MS, a ...
Guest writer Reché Jones says it took her years to be diagnosed with relapsing-remitting MS. Now she plans to "keep moving." ...
Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients. The ...
Dr Pavan Bhargava recently returned from the 2025 AAN Annual Meeting, where key updates in relapsing-remitting multiple sclerosis (RRMS) were highlighted. He noted the introduction of the 2024 ...
Secondary progressive multiple sclerosis (SPMS) can develop after relapsing-remitting multiple sclerosis (RRMS). It causes steady neurological decline, either with or without relapses. Switching from ...
Secondary progressive multiple sclerosis (SPMS) usually develops after years of relapsing-remitting multiple sclerosis (RRMS) and leads to steadily worsening symptoms and disability over time. SPMS ...
medwireNews: The DECIDE study shows that 4-weekly daclizumab high-yield process (HYP) reduces disease activity in patients with relapsing–remitting multiple sclerosis (MS) more effectively than weekly ...
A registry study led by the University of Oulu examined the early-stage treatment of relapsing-remitting multiple sclerosis (MS) in Finland between 2013 and 2022. According to the study, MS treatment ...
– Enrollment Completed for Both Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Top-Line Data Expected End of 2026 – – Additional Data from Phase 2 CALLIPER Trial in ...
- MUSETTE trial was designed to determine whether a higher dose of the currently approved Ocrevus IV 600 mg would provide additional benefit to people living with relapsing multiple sclerosis - - The ...
Hosted on MSN
Physical fitness associated with better cognition in people with relapsing-remitting MS
Good physical performance is associated with better cognition in people with relapsing-remitting MS, according to a recent study by the University of Eastern Finland. Good functional capacity was also ...
- Targeted enrollment of 168 RRMS patients achieved in December 2024 - The last patient is expected to complete the trial in the third quarter of 2025 SAN DIEGO--(BUSINESS WIRE)-- Contineum ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results